Results 81-100 of 146 for drugs speaker:Louise O'Reilly

Written Answers — Department of Health: Drugs Payment Scheme Data (8 Mar 2018)

Louise O'Reilly: 279. To ask the Minister for Health the average gross costs of the drugs payment scheme by item in each of the years 2007 to 2017, in tabular form; and if he will make a statement on the matter. [10913/18]

Written Answers — Department of Health: Misuse of Drugs (20 Feb 2018)

Louise O'Reilly: 376. To ask the Minister for Health when bulletin 7 of the drug prevalence survey 2014-2015 which focuses on gambling will be published in view of the fact that it was to be released in 2017; and if he will make a statement on the matter. [8551/18]

Other Questions: Medicinal Products Regulation (15 Nov 2017)

Louise O'Reilly: 30. To ask the Minister for Health his plans to undertake an investigation into the current and historical use of the drug, sodium valproate; if a State-wide register of those women who were on the medicine during pregnancy, and of the children affected by foetal anti-convulsant syndrome caused by exposure to sodium valproate during pregnancy, will be established; if appropriate pathways for...

Other Questions: Medicinal Products Regulation (15 Nov 2017)

Louise O'Reilly: ...1,000 tablets, the risk is the same. The risks are known. In advance of any reports, since we know the potential risks to women of child-bearing potential - the HSE's phrase - who are taking this drug, the Minister should instruct his officials to ensure that information is communicated. The woman in question communicated with the pharmacy, part of a large chain. It has apologised but...

Other Questions: Medicinal Products Regulation (15 Nov 2017)

Louise O'Reilly: ...better. The actions being taken now are somewhat for the future. I have met some of the women affected and their children, some of whom are adults. They have been profoundly affected by this drug. I am not a scientist or a doctor. I cannot make that equivalence but I have met them. These children suffer from a range of conditions. As the Minister is aware, it can give rise to...

Written Answers — Department of Health: Medicinal Products Reimbursement (15 Nov 2017)

Louise O'Reilly: 99. To ask the Minister for Health his views on the need for a dedicated policy for the approval and reimbursement of orphan drugs for rare diseases, which is separate to the current policy, in view of the fact that the national rare disease plan for Ireland 2014-2018 recommended the bringing forward of appropriate decision criteria for the reimbursement of orphan rare medicines and...

Leaders' Questions (9 Nov 2017)

Louise O'Reilly: At the end of September the European Medicines Agency in London held a public hearing on the epilepsy drug sodium valproate, better known in Ireland as Epilim. The purpose of the hearing was to consider whether the warning against taking the drug while pregnant was strong enough. It followed on from a review in 2014 based on which the European Medicines Agency took the decision to...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Louise O'Reilly: ...would apportion blame equally to all involved in this. The patients and their families have been left in Limbo in a way that is actually quite cruel for them. They are in a situation whereby the drug they need is being provided on a compassionate basis. I do not think there is much compassion in global pharmaceuticals but that is the term that is used. On a compassionate basis that...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Louise O'Reilly: All members have done some research on the issue. Is it correct that there are young children on the drug in the countries the witness listed where conditional access has been granted?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Louise O'Reilly: Let us take Britain as an example. In England and Northern Ireland the drug is being reimbursed. Is that being done on a conditional basis or otherwise?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Louise O'Reilly: The families of the kids who are waiting to hear about the availability of this drug are very anxious and are watching these proceedings. They do not believe a mistake was made but, rather, a certain amount of compassion was shown. With regard to most of the countries where it is available or the countries the witness listed where it is not available in any form, conditional or otherwise,...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Louise O'Reilly: I wish to ask for clarification on that issue. Is anyone at the moment on a programme that for whatever reason has not received full endorsement where the HSE is administering the drug? The difficulty that arises for those people is who is going to administer the drug. Is anyone at the moment having the drug administered by the HSE even though it is not necessarily being fully refunded?...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Louise O'Reilly: No, I am asking about patients who are separate to that and whether there is a scenario in the HSE whereby people are on a drug but the HSE is not administering it so there is no protocol that exists other than the one for the management of people at the end of clinical trials.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Louise O'Reilly: ...what was said earlier. If there is anything that we can do, from a legislative perspective, to make the process easier and eliminate problems then we should consider doing so. In terms of the drug Kuvan, Mr. Hennessy talked about stakeholder involvement earlier. I understand that the HSE is not hostile to the initiative but there does not seem to be a structured mechanism to allow...

Written Answers — Department of Defence: Defence Forces Medicinal Products (18 Oct 2017)

Louise O'Reilly: 59. To ask the Taoiseach and Minister for Defence the efforts which have been made to withdraw and replace the anti-malaria drug Lariam and implement the proposals contained in the cross-party motion that was passed in the previous Dáil Éireann term; and if he will make a statement on the matter. [44035/17]

Joint Oireachtas Committee on Health: Estimates for Public Services 2017: Vote 38 - Department of Health (27 Sep 2017)

Louise O'Reilly: ...kind of news gets published at 6 p.m. on a Friday and it is not good news. Many of the questions I had have been asked. There is a section in the document for the National Advisory Council on Drugs but there is no money put beside it. That jumped out at me. Perhaps the Minister would be good enough to explain what that is. The maternity strategy has been mentioned already. I...

Written Answers — Department of Health: Medicinal Products Data (26 Jul 2017)

Louise O'Reilly: ...who would benefit from each of the nine medicines approved by the HSE but are without the funds to be purchased (details supplied); the estimated number of persons that would benefit from the drug, in tabular form; and if he will make a statement on the matter. [35175/17]

Written Answers — Department of Health: Drugs Payment Scheme (26 Jul 2017)

Louise O'Reilly: 721. To ask the Minister for Health the cost of lowering the threshold of the drugs payment scheme from €144 to €132, in tabular form; and if he will make a statement on the matter. [35182/17]

Written Answers — Department of Health: Sexually Transmitted Infections (26 Jul 2017)

Louise O'Reilly: ...on pre-exposure prophylaxis; the stage in this project the HSE is currently at; if PrEP should be found feasible for HSE availability, if funding will be available to facilitate access to this drug, should that be found feasible; and if he will make a statement on the matter. [35887/17]

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: The purpose of this session is to engage with the HSE and the National Centre for Pharmacoeconomics, NCPE, on the processes and criteria used when evaluating orphan drugs. On behalf of the committee I welcome Mr. John Hennessy, Mr. Shaun Flanagan and Mr. Ray Mitchell of the HSE; Professor Michael Barry and Dr. Lesley Tilson of the NCPE. By virtue of section 17(2)(l) of the Defamation Act...